Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

This study is looking for adults and teenagers (aged 12 to under 18) who weigh at least 40 kg and have moderate to severe eczema. To be considered, your eczema must have been present for at least a year and covers at least 10% of your body. Your eczema must also be severe enough that your doctor considers it appropriate for a stronger medication, and you must have tried and not responded well to usual creams and ointments, or your doctor feels these aren't suitable for you.

To help assess your current symptoms, you'll need to complete a daily electronic diary about your itching and sleep for at least four days in the week before the study officially starts. You must also be willing and able to attend all clinic visits and complete any questionnaires involved in the study.

There are also some reasons why you might not be able to join. For example, if you've previously taken certain specific medications for eczema (like tralokinumab, lebrikizumab, or certain oral JAK inhibitors), you wouldn't be eligible. Also, if you have other serious uncontrolled health conditions like severe asthma, or if you've had a severe allergic reaction (anaphylaxis) in the past, you generally wouldn't be able to participate.

If you decide to take part in this study, you would receive the medication lebrikizumab according to the study plan. You would need to attend regular clinic visits to allow the study team to check on your eczema symptoms, collect blood samples, and monitor your overall health and any side effects. You will also be asked to continue completing an electronic diary about your symptoms, specifically your itching and how it affects your sleep. The main treatment part of the study lasts for 24 weeks, but there might be a follow-up period afterward. You will be given clear instructions on what to expect for each visit and assessment.